Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| minor |
ESMYA offers a minor improvement in actual benefit (IAB IV) compared to leuprorelin in terms of tolerability in the pre-operative treatment of moderate to severe symptoms in uterine fibroids in adult women of childbearing potential. |
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
9XEpgweK9GE5dNMj
